Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)
China
· Delayed Price · Currency is CNY 6.17
+0.26 (4.40%)
At close: Mar 10, 2026
SHA:688373 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 141.77 | 130.27 | 90.78 | 48.21 | 7.66 | Upgrade
|
| Revenue Growth (YoY) | 8.83% | 43.51% | 88.31% | 529.33% | - | Upgrade
|
| Cost of Revenue | - | 22.41 | 16.7 | 8.82 | 0.76 | Upgrade
|
| Gross Profit | 141.77 | 107.87 | 74.08 | 39.38 | 6.9 | Upgrade
|
| Selling, General & Admin | - | 176.79 | 168.57 | 146.18 | 124.38 | Upgrade
|
| Research & Development | - | 368.56 | 344.86 | 150.39 | 151.76 | Upgrade
|
| Other Operating Expenses | 386.85 | 0.41 | 0.3 | 0.14 | 0.03 | Upgrade
|
| Operating Expenses | 386.85 | 546.53 | 514.06 | 296.9 | 276.2 | Upgrade
|
| Operating Income | -245.07 | -438.66 | -439.98 | -257.52 | -269.3 | Upgrade
|
| Interest Expense | - | -11.15 | -10.14 | -8.82 | -5.23 | Upgrade
|
| Interest & Investment Income | - | 2.37 | 2.19 | 4.4 | 2.39 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -4.52 | 0.02 | -5.59 | -0.29 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.49 | -1 | -0.13 | 0.34 | -0.4 | Upgrade
|
| EBT Excluding Unusual Items | -245.57 | -452.96 | -448.03 | -267.19 | -272.82 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 17.08 | 33.34 | 18.49 | 10.53 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.03 | 0 | 0.49 | -0.02 | Upgrade
|
| Other Unusual Items | - | 1.34 | -0.46 | 27.92 | 36.08 | Upgrade
|
| Pretax Income | -245.57 | -434.51 | -415.15 | -220.29 | -226.23 | Upgrade
|
| Income Tax Expense | -3.95 | 6.21 | 5.97 | 0.01 | 0.04 | Upgrade
|
| Net Income | -241.61 | -440.72 | -421.12 | -220.3 | -226.27 | Upgrade
|
| Net Income to Common | -241.61 | -440.72 | -421.12 | -220.3 | -226.27 | Upgrade
|
| Shares Outstanding (Basic) | 653 | 656 | 656 | 580 | 526 | Upgrade
|
| Shares Outstanding (Diluted) | 653 | 656 | 656 | 580 | 526 | Upgrade
|
| Shares Change (YoY) | -0.40% | - | 13.09% | 10.17% | 106.16% | Upgrade
|
| EPS (Basic) | -0.37 | -0.67 | -0.64 | -0.38 | -0.43 | Upgrade
|
| EPS (Diluted) | -0.37 | -0.67 | -0.64 | -0.38 | -0.43 | Upgrade
|
| Free Cash Flow | - | -448.1 | -336.74 | -252.18 | -203.89 | Upgrade
|
| Free Cash Flow Per Share | - | -0.68 | -0.51 | -0.43 | -0.39 | Upgrade
|
| Gross Margin | 100.00% | 82.80% | 81.61% | 81.70% | 90.08% | Upgrade
|
| Operating Margin | -172.86% | -336.72% | -484.69% | -534.19% | -3515.62% | Upgrade
|
| Profit Margin | -170.42% | -338.31% | -463.91% | -456.99% | -2953.91% | Upgrade
|
| Free Cash Flow Margin | - | -343.97% | -370.96% | -523.13% | -2661.81% | Upgrade
|
| EBITDA | -242.81 | -436.4 | -437.97 | -256.22 | -268.75 | Upgrade
|
| EBITDA Margin | -171.27% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 2.26 | 2.26 | 2.02 | 1.29 | 0.55 | Upgrade
|
| EBIT | -245.07 | -438.66 | -439.98 | -257.52 | -269.3 | Upgrade
|
| EBIT Margin | -172.86% | - | - | - | - | Upgrade
|
| Revenue as Reported | - | 130.27 | 90.78 | 48.21 | 7.66 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.